神经退行性疾病是神经元结构或功能逐渐丧失甚至死亡而导致功能障的一类疾病，包括肌萎缩侧索硬化症、帕金森病、阿尔茨海默病、亨廷顿氏病以及脊髓性肌萎缩症等等。目前，这类疾病病因尚不明确也无法治愈，严重威胁着人类健康与日常生活。另外，中国健康医疗领域已成长为一个约4 万亿的市场，过去的5 年一直保持在超20% 的年复合增长率，预计在未来的5 年，市场还将翻一番达到8 万亿，接近全国GDP 的10%。
Neurodegeneration is the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative diseases – including amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, and Huntington's disease – occur as a result of neurodegenerative processes. Such diseases are incurable, resulting in progressive degeneration and/or death of neuron cells. Neurodegenerative diseases have severe impact on the physical health and life quality. Up to now, no wonder drug has been found which can cure it.
From 2015 to 2035, China will face the dilemma of rapidly ageing populations. The number of old people will increase from 212 million to 418 million and account for 29% of the total population. Just to cite two representative diseases, Alzheimer's disease and Parkinson's disease.
In China, people over 65 years old will have 14.4% incidence of Parkinson's disease, and the yearly new patients is around 100 thousand, showing a rapid increase. Right now, there are more than two million and five hundred thousand Chinese sufferings from Parkinson.
Additionally, China has the largest and fastest-growing number of patients with Alzheimer's in the world, more than 8 million. The prevalence rate of Alzheimer's is 3.21% for people who over 65 years old. The number of patients is expected to be more than 20 million by 2050.
On the other hand, there is a 4 trillion market of healthcare created in China. In the past 5 years, it had a stable annual compound growth over 20%. In addition, this market is expected to double to 8 trillion in the next 5 years, approaches the level of 10% of the national GDP.
A primary goal of the meeting is to provide a symposium where medical scientists from academia can interact with clinician and scientists from the biopharmaceutical industry, thus forging a community of academic and industry researchers who recognize that they have much to learn from each other. Rational drug discovery for neurodegenerative diseases has begun to yield compounds and treatments that are now entering clinical settings. For human studies utilizing these compounds and treatments to be maximally informative, it is crucial that scientists from academia clinician and industry meet regularly to exchange data and ideas.
Organizing Committee of 2018 Neurodegenerative Diseases Symposium
All plans come with unlimited disk space. Our support can be as quick as 15 minutes to get a response. Sed non
mauris vitae erat consequat auctor eu in elit. Class aptent taciti sociosqu.
Sed non neque elit. Sed ut imperdiet nisi. Proin condimentum fermentum nunc. Etiam pharetra, erat sed fermentum
feugiat velit mauris egestas quamut aliquam massa nisl quis neque. Suspendisse in orci enim.